Rafferty Asset Management
KRYS icon

Rafferty Asset Management’s Krystal Biotech KRYS Stock Holding History

Rafferty Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.28M Sell
8,836
-8,851
-50% -$2.64M 0.01% 507
2026
Q1 		$4.57M Sell
17,687
-6,581
-27% -$1.75M 0.02% 414
2025
Q4 		$5.98M Sell
24,268
-10,372
-30% -$2.18M 0.02% 379
2025
Q3 		$6.11M Sell
34,640
-25
-0.1% -$3.74K 0.02% 384
2025
Q2 		$4.77M Buy
34,665
+10,504
+43% +$1.54M 0.02% 412
2025
Q1 		$4.36M Sell
24,161
-3,040
-11% -$511K 0.02% 400
2024
Q4 		$4.26M Sell
27,201
-18,639
-41% -$3.31M 0.02% 447
2024
Q3 		$8.34M Buy
45,840
+4,040
+10% +$779K 0.03% 312
2024
Q2 		$7.68M Sell
41,800
-11,567
-22% -$1.94M 0.03% 324
2024
Q1 		$9.5M Sell
53,367
-30,654
-36% -$4.26M 0.04% 280
2023
Q4 		$10.4M Buy
84,021
+12,215
+17% +$1.35M 0.04% 265
2023
Q3 		$8.33M Buy
71,806
+18,623
+35% +$2.27M 0.05% 275
2023
Q2 		$6.24M Sell
53,183
-8,341
-14% -$852K 0.04% 364
2023
Q1 		$4.93M Sell
61,524
-101
-0.2% -$7.93K 0.03% 388
2022
Q4 		$4.88M Buy
61,625
+9,369
+18% +$695K 0.04% 380
2022
Q3 		$3.64M Buy
52,256
+19,064
+57% +$1.38M 0.04% 385
2022
Q2 		$2.18M Sell
33,192
-26,820
-45% -$1.67M 0.02% 444
2022
Q1 		$3.99M Buy
60,012
+27,519
+85% +$1.72M 0.02% 432
2021
Q4 		$2.27M Buy
32,493
+9,239
+40% +$538K 0.01% 611
2021
Q3 		$1.21M Buy
23,254
+892
+4% +$52.8K 0.01% 763
2021
Q2 		$1.52M Sell
22,362
-3,596
-14% -$251K 0.01% 757
2021
Q1 		$2M Buy
25,958
+21,665
+505% +$1.58M 0.01% 628
2020
Q4 		$258K Sell
4,293
-8,732
-67% -$436K ﹤0.01% 887
2020
Q3 		$561K Buy
13,025
+5,300
+69% +$230K 0.01% 672
2020
Q2 		$320K Buy
+7,725
New +$372K ﹤0.01% 814
2020
Q1 		– Sell
-12,522
Closed -$693K – 715
2019
Q4 		$693K Sell
12,522
-14,110
-53% -$692K 0.01% 629
2019
Q3 		$925K Buy
+26,632
New +$1.19M 0.01% 558

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Rafferty Asset Management's KRYS Position: Q2 2026 in Review

Rafferty Asset Management reduced its Krystal Biotech (KRYS) stake by 50% in Q2 2026, selling an estimated $2.64M and leaving 8,836 shares worth $3.28M. The position accounts for 0.01% of the portfolio, ranked #507.

Rafferty Asset Management first reported a position in KRYS in Q3 2019 and has held it in 27 quarters since. The position peaked at $10.4M in Q4 2023. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Rafferty Asset Management held 8,836 shares of Krystal Biotech worth $3.28M as of Q2 2026.
  • Rafferty Asset Management sold 8,851 Krystal Biotech shares in Q2 2026, an estimated $2.64M.
  • Krystal Biotech made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #507 holding.
  • Rafferty Asset Management first reported a position in Krystal Biotech in Q3 2019 and has held it in 27 quarters since.
  • Rafferty Asset Management's Krystal Biotech position peaked at $10.4M in Q4 2023.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.